1 / 13

Patent Ductus Arteriosus Occlusion Device Oral Presentation #2

Patent Ductus Arteriosus Occlusion Device Oral Presentation #2. Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle. Patent Ductus Arteriosus (PDA). Ductus arteriosus (DA) allows blood to bypass pulmonary and enter systemic

jgoodson
Download Presentation

Patent Ductus Arteriosus Occlusion Device Oral Presentation #2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patent Ductus Arteriosus Occlusion DeviceOral Presentation #2 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle 2/14/2003

  2. Patent Ductus Arteriosus (PDA) • Ductus arteriosus (DA) allows blood to bypass pulmonary and enter systemic • DA normally closes within 10-18 hrs of delivery (if not deemed abnormal/patent) • PDA affects 1800 babies/year in USA alone • Many adverse effects • growth retardation, breathlessness or lack of appetite • Most common problem is congestive heart failure 2/14/2003

  3. Current Treatments • Drug therapy (indomethacin) • Implantable devices (most common are coils) • Usually need 3-4 coils • Difficult to remove and reposition • Invasive surgery (ligate the PDA to inhibit blood flow) 2/14/2003

  4. Project Goals • To design, develop and patent a PDA occlusion device that can… • Be delivered via a catheter • Conform to the shape of the PDA and cause occlusion • Can be repositioned easily • Be cost effective (<$200) • Provide an initial success rate of 100% • More patient friendly procedure 2/14/2003

  5. Effect of Occlusion Device 2/14/2003

  6. Our Design 2/14/2003

  7. Delivery Path of Device 2/14/2003

  8. Foam Issues • We can make a polyurethane foam with methylene bisphenyl diisocyanate (MDI), polytetramethylene glycol (PTMEG), 1,4-butanediol and water. • In touch with chemical engineering professors at Vanderbilt. • Also looking to make corporate contacts. 2/14/2003

  9. Work Completed • Conducted extensive research on other treatment methods (to avoid short comings on our design) • Met with Dr. Doyle to discuss our progress and future goals • Locating a company from which to purchase chemicals. • Have ordered Nitinol memory wire in two different diameter thicknesses • Have secured an In-Vitro PDA Simulation device for testing 2/14/2003

  10. Current Status • Making final design refinements to device • Developing life-size PDA device prototype • Developing equations to model PDA testing apparatus • Making arrangements with Mechanical Engineering professor to have Nitinol wire machined here at Vanderbilt • Completing Design Safe and Innovation Work Bench assignments • Making necessary modifications to website 2/14/2003

  11. Needs • Obtain missing foam ingredient (PTMEG) • Make arrangements to machine Nitinol wire • Meet with Dr. Doyle to discuss further progress 2/14/2003

  12. Future Direction • Build scaled prototype with correct biomaterials • Figure out best way to secure Nitinol within device • Begin conducting pressure and durability tests in PDA simulated environment • Refine design based on testing • Talk with Dr. Doyle/Office of Technology Transfer about patenting this PDA Occlusion Device 2/14/2003

  13. Contact Information • David Brogan • david.m.brogan@vanderbilt.edu • 1-210-364-4546 • Darci Phillips • darci.j.phillips@vanderbilt.edu • 1-615-386-9015 • Daniel Schultz • daniel.j.schultz@vanderbilt.edu • 1-615-421-6067 2/14/2003

More Related